- Home
- CYH vs CRMD Comparison
CYH vs CRMD Comparison
Compare CYH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | CRMD |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.4M | 943.9M |
| IPO Year | 1991 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CYH | CRMD |
|---|---|---|
| Price | $3.21 | $12.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $3.73 | ★ $17.43 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 02-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.47 | 2.25 |
| Revenue | ★ $12,644,000,000.00 | $214,303,672.00 |
| Revenue This Year | $0.04 | $627.89 |
| Revenue Next Year | $0.86 | $40.95 |
| P/E Ratio | ★ $1.31 | $5.56 |
| Revenue Growth | 0.74 | ★ 1647.67 |
| 52 Week Low | $2.24 | $5.60 |
| 52 Week High | $4.47 | $17.43 |
Technical Indicators
Market Signals| Indicator | CYH | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 68.45 |
| Support Level | $3.15 | $11.78 |
| Resistance Level | $3.34 | $12.51 |
| Average True Range (ATR) | 0.11 | 0.50 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 23.76 | 94.53 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.